Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Recommendation of “Hold” from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given a consensus rating of “Hold” by the fifteen brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $486.6667.

A number of brokerages recently issued reports on MEDP. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and lowered their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target for the company in a report on Friday, March 6th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target for the company in a report on Tuesday, February 10th. Finally, Leerink Partners lowered their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th.

Medpace Stock Performance

MEDP stock opened at $496.00 on Tuesday. The company’s 50 day moving average price is $479.92 and its 200 day moving average price is $537.47. The firm has a market capitalization of $14.17 billion, a price-to-earnings ratio of 32.42, a PEG ratio of 2.39 and a beta of 1.39. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Several large investors have recently modified their holdings of MEDP. NewEdge Advisors LLC boosted its holdings in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Medpace in the second quarter valued at approximately $296,000. Finally, American Century Companies Inc. boosted its holdings in shares of Medpace by 13.7% in the second quarter. American Century Companies Inc. now owns 12,717 shares of the company’s stock valued at $3,991,000 after acquiring an additional 1,529 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.